BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...SD ongoing at 44-45 weeks 4097 VasGene Therapeutics Inc. sEphB4 Fusion protein of soluble EPH receptor B4 (EPHB4...
BioCentury | Dec 8, 2017
Translation in Brief

ADAM and Ephrin

...soluble form of the ephrin, which triggered a pathway involving ephrin B3 receptor (EPHB3) and EPHB4...
...2017) Mark Zipkin, Staff Writer Harvard Medical School University of Montreal ADAM metallopeptidase domain 10 (ADAM10) EPH receptor B3 (EPHB3) EPH receptor B4 (EPHB4) Ephrin...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse studies suggest inhibiting the β amyloid - EPHB2 interaction could help treat AD. In a mouse model of AD, intrahippocampal injection of a peptide inhibitor of the β amyloid-EPHB2 interaction increased...
BioCentury | Sep 15, 2016
Distillery Techniques

Techniques: Kinase-inactivating mutations in EPH receptor B4 (EPHB4) as risk markers for lymphatic-related hydrops fetalis

...Biomarkers TECHNOLOGY: Gene profiling Kinase-inactivating EPHB4 mutations in parents or fetuses could help predict the risk...
...with no history of the disease. In HEK cell cultures, EPHB4 proteins encoded by mutant EPHB4...
...larger cohort of families with a history of the disease. DESCRIPTION: Kinase-inactivating mutations in EPH receptor B4 (EPHB4...
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma EPH receptor B4 (EPHB4); platelet derived growth...
...B (PDGFRB; PDGFR1; CD140B) Patient sample and mouse studies suggest inhibiting PDGFRB cross talk with EPHB4...
...patients and mouse models, EPHB4 and PDGFRB were upregulated. In human and mouse aRMS cells, EPHB4...
BioCentury | Oct 10, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms MicroRNA and small interfering RNA combination therapy for cancer Mouse and cell culture studies suggest combined use of miRNA and siRNA against a target could...
BioCentury | Sep 29, 2011
Targets & Mechanisms

Subtyping lessons in brain cancer

A team at St. Jude Children's Research Hospital believes a screening approach based on disease subtypes will be important for identifying therapeutics for brain cancer patients. As a proof of principle, the researchers conducted a...
BioCentury | Aug 1, 2011
Product Development

Simple fix for EGFR resistance

...a small molecule inhibitor of multiple receptor tyrosine kinases including EGFR, HER2, VEGF receptor and EphB4...
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Neurology Pain EPH receptor B1 (EPHB1) Rat studies suggest inhibiting EPHB1 signaling could help treat bone cancer pain and prevent morphine tolerance. In a rat model of bone cancer pain, spinal...
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Autoimmune disease Autoimmune disease CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An...
Items per page:
1 - 10 of 35